It's Time to Give the World's Deadliest Disease Orphan Status

Fordyce CB , Roe MT , Ahmad T , et al. Cardiovascular Drug Development: Is It Dead or Just Hibernating?. J. Am. Coll. Cardiol . 2015; 65: 1567–1582.

Thomas D , Wessel C . The State of Innovation in Highly Prevalent Chronic Diseases. Volume V: Systemic Hypertension and Congestive Heart Failure. BIO Industry Analysis Report (Highly Prevalent Chronic Disease Series). BIO; 2020.

Downing NS , Aminawung JA , Shah ND , et al. Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005–2012. 2014; JAMA , 311: 368–377.

Wood S . Glory—Is cancer beating cardiovascular disease?. Medscape . https://www.medscape.com/viewarticle/791006. Published: August 18, 2021.

European Medicines Agency. Rare diseases, orphan medicines: Getting the facts straight. Report No. EMA/551338/2017. https://www.ema.europa.eu/en/documents/other/rare-diseases-orphan-medicines-getting-facts-straight_en.pdf. February 28, 2018.

Fidler B . A record number of biotechs are going public. Here's how they're performing. BioPharma Dive . https://www.biopharmadive.com/news/biotech-ipo-performance-tracker/587604/. Accessed: June 26, 2021.

Jackson N , Atar D , Borentain M , et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur. Heart J . 2016; 37: 747–754.

Eder J , Sedrani R , Wiesmann C . The discovery of first-in-class drugs: origins and evolution. Nat. Rev. Drug Discov. , 2014; 13: 577–587.

Aitken M , Kleinrock M . Orphan Drugs in the United States: Exclusivity, Pricing and Treated Populations. IQVIA Institute for Human Data Science. December 2018.